91ÖĆƬł§

Published on Market Research Reports® Inc. ()

Home > Global Certolizumab Pegol Market Insights, Forecast to 2030

Global Certolizumab Pegol Market Insights, Forecast to 2030

Publication ID: 
PB512242671
Publication Date: 
December 24, 2024
Pages: 
71
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 4,900.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Healthcare [2]
Pharma & Healthcare [3]
Description: 

Certolizumab pegol (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Market Analysis and Insights: Global Certolizumab Pegol Market
The global Certolizumab Pegol market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Certolizumab Pegol is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Certolizumab Pegol is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Certolizumab Pegol is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Certolizumab Pegol include UCB. etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Certolizumab Pegol is widely used in various fields, such as Crohn’s disease, Active rheumatoid arthritis and Active psoriatic arthritis,, etc. Crohn’s disease provides greatest supports to the Certolizumab Pegol industry development. In 2023, global % revenue of Certolizumab Pegol went into Crohn’s disease filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Certolizumab Pegol market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Certolizumab Pegol, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Certolizumab Pegol, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Certolizumab Pegol revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Certolizumab Pegol market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Certolizumab Pegol revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
UCB
Segment by Type
Single-dose vial
Single-dose prefilled syringe
Segment by Application
Crohn’s disease
Active rheumatoid arthritis
Active psoriatic arthritis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Certolizumab Pegol in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Certolizumab Pegol companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Certolizumab Pegol revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Certolizumab Pegol Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Single-dose vial
1.2.3 Single-dose prefilled syringe
1.3 Market by Application
1.3.1 Global Certolizumab Pegol Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Crohn’s disease
1.3.3 Active rheumatoid arthritis
1.3.4 Active psoriatic arthritis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Certolizumab Pegol Market Perspective (2019-2030)
2.2 Global Certolizumab Pegol Growth Trends by Region
2.2.1 Certolizumab Pegol Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Certolizumab Pegol Historic Market Size by Region (2019-2024)
2.2.3 Certolizumab Pegol Forecasted Market Size by Region (2025-2030)
2.3 Certolizumab Pegol Market Dynamics
2.3.1 Certolizumab Pegol Industry Trends
2.3.2 Certolizumab Pegol Market Drivers
2.3.3 Certolizumab Pegol Market Challenges
2.3.4 Certolizumab Pegol Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Certolizumab Pegol by Players
3.1.1 Global Certolizumab Pegol Revenue by Players (2019-2024)
3.1.2 Global Certolizumab Pegol Revenue Market Share by Players (2019-2024)
3.2 Global Certolizumab Pegol Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Certolizumab Pegol, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Certolizumab Pegol Market Concentration Ratio
3.4.1 Global Certolizumab Pegol Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Certolizumab Pegol Revenue in 2023
3.5 Global Key Players of Certolizumab Pegol Head office and Area Served
3.6 Global Key Players of Certolizumab Pegol, Product and Application
3.7 Global Key Players of Certolizumab Pegol, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Certolizumab Pegol Breakdown Data by Type
4.1 Global Certolizumab Pegol Historic Market Size by Type (2019-2024)
4.2 Global Certolizumab Pegol Forecasted Market Size by Type (2025-2030)
5 Certolizumab Pegol Breakdown Data by Application
5.1 Global Certolizumab Pegol Historic Market Size by Application (2019-2024)
5.2 Global Certolizumab Pegol Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Certolizumab Pegol Market Size (2019-2030)
6.2 North America Certolizumab Pegol Market Size by Type
6.2.1 North America Certolizumab Pegol Market Size by Type (2019-2024)
6.2.2 North America Certolizumab Pegol Market Size by Type (2025-2030)
6.2.3 North America Certolizumab Pegol Market Share by Type (2019-2030)
6.3 North America Certolizumab Pegol Market Size by Application
6.3.1 North America Certolizumab Pegol Market Size by Application (2019-2024)
6.3.2 North America Certolizumab Pegol Market Size by Application (2025-2030)
6.3.3 North America Certolizumab Pegol Market Share by Application (2019-2030)
6.4 North America Certolizumab Pegol Market Size by Country
6.4.1 North America Certolizumab Pegol Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Certolizumab Pegol Market Size by Country (2019-2024)
6.4.3 North America Certolizumab Pegol Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Certolizumab Pegol Market Size (2019-2030)
7.2 Europe Certolizumab Pegol Market Size by Type
7.2.1 Europe Certolizumab Pegol Market Size by Type (2019-2024)
7.2.2 Europe Certolizumab Pegol Market Size by Type (2025-2030)
7.2.3 Europe Certolizumab Pegol Market Share by Type (2019-2030)
7.3 Europe Certolizumab Pegol Market Size by Application
7.3.1 Europe Certolizumab Pegol Market Size by Application (2019-2024)
7.3.2 Europe Certolizumab Pegol Market Size by Application (2025-2030)
7.3.3 Europe Certolizumab Pegol Market Share by Application (2019-2030)
7.4 Europe Certolizumab Pegol Market Size by Country
7.4.1 Europe Certolizumab Pegol Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Certolizumab Pegol Market Size by Country (2019-2024)
7.4.3 Europe Certolizumab Pegol Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Certolizumab Pegol Market Size (2019-2030)
8.2 China Certolizumab Pegol Market Size by Type
8.2.1 China Certolizumab Pegol Market Size by Type (2019-2024)
8.2.2 China Certolizumab Pegol Market Size by Type (2025-2030)
8.2.3 China Certolizumab Pegol Market Share by Type (2019-2030)
8.3 China Certolizumab Pegol Market Size by Application
8.3.1 China Certolizumab Pegol Market Size by Application (2019-2024)
8.3.2 China Certolizumab Pegol Market Size by Application (2025-2030)
8.3.3 China Certolizumab Pegol Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Certolizumab Pegol Market Size (2019-2030)
9.2 Asia Certolizumab Pegol Market Size by Type
9.2.1 Asia Certolizumab Pegol Market Size by Type (2019-2024)
9.2.2 Asia Certolizumab Pegol Market Size by Type (2025-2030)
9.2.3 Asia Certolizumab Pegol Market Share by Type (2019-2030)
9.3 Asia Certolizumab Pegol Market Size by Application
9.3.1 Asia Certolizumab Pegol Market Size by Application (2019-2024)
9.3.2 Asia Certolizumab Pegol Market Size by Application (2025-2030)
9.3.3 Asia Certolizumab Pegol Market Share by Application (2019-2030)
9.4 Asia Certolizumab Pegol Market Size by Region
9.4.1 Asia Certolizumab Pegol Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Certolizumab Pegol Market Size by Region (2019-2024)
9.4.3 Asia Certolizumab Pegol Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Certolizumab Pegol Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Type
10.2.1 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Certolizumab Pegol Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Application
10.3.1 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Certolizumab Pegol Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Country
10.4.1 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Certolizumab Pegol Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 UCB
11.1.1 UCB Company Details
11.1.2 UCB Business Overview
11.1.3 UCB Certolizumab Pegol Introduction
11.1.4 UCB Revenue in Certolizumab Pegol Business (2019-2024)
11.1.5 UCB Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned: 

UCB

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-certolizumab-pegol-market-insights-forecast-2030

Links
[1] /countries/global[2] /healthcare[3] /pharma-healthcare